Monopar Therapeutics Inc
$ 114.66
6.73%
30 Jul - close price
- Market Cap 719,647,000 USD
- Current Price $ 114.66
- High / Low $ 116.52 / 106.59
- Stock P/E N/A
- Book Value 20.21
- EPS -1.90
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.16 %
- 52 Week High 116.64
- 52 Week Low 29.18
About
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Analyst Target Price
$116.85
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-27 | 2025-11-13 | 2025-08-12 | 2025-05-13 | 2025-03-31 | 2024-11-08 | 2024-08-09 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.46 | -0.61 | -0.48 | -0.35 | -0.38 | -2.75 | -1.85 | -0.5 | -0.5 | -0.12 | -0.7 | -0.8 |
| Estimated EPS | -0.8975 | -0.51 | -0.4 | -0.48 | -0.57 | -0.42 | -1.17 | -0.47 | -0.85 | -0.15 | -0.95 | -0.95 |
| Surprise | 0.4375 | -0.1 | -0.08 | 0.13 | 0.19 | -2.33 | -0.68 | -0.03 | 0.35 | 0.03 | 0.25 | 0.15 |
| Surprise Percentage | 48.7465% | -19.6078% | -20% | 27.0833% | 33.3333% | -554.7619% | -58.1197% | -6.383% | 41.1765% | 20% | 26.3158% | 15.7895% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNPR
2026-07-28 01:11:05
Monopar Therapeutics Inc (MNPR) has an institutional shareholding score of 7.00, placing it 80th out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 88.03%, marking a 29.07% increase quarter-over-quarter. Janus Henderson Investors, RA Capital Management, LP, and Adage Capital Management, L.P. are among the largest institutional shareholders.
2026-07-28 00:32:47
The article provides a detailed historical overview of Monopar Therapeutics Inc (MNPR) dividends and stock splits. It indicates that no dividends have been distributed by the company over the past five years and lists multiple upcoming stock splits of type "Merger" with a 5-to-1 ratio, all scheduled for August 9, 2024. The page also shows current stock performance data for MNPR.
2026-07-27 07:44:04
This article details the shareholder structure of Monopar Therapeutics Inc (MNPR), listing its major shareholders and institutional holdings. Key institutional investors include Janus Henderson Investors, RA Capital Management, L.P., and Adage Capital Management, L.P., alongside an overview of institutional shareholding trends over recent quarters. It also provides a breakdown of shareholder types and related ETF holdings.
2026-07-26 16:40:12
This article from TradingKey reports on Monopar Therapeutics Inc (MNPR)'s revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article also provides the current stock trading information for MNPR.
2026-07-24 12:12:16
H.C. Wainwright has raised its target price for MONOPAR THERAPEUTICS INC. to $125 from the previous $105. This news was reported by Reuters. The article is very short, focusing solely on this price update.
2026-07-23 12:10:53
H.C. Wainwright has increased its price target for Monopar Therapeutics (NASDAQ:MNPR) to $125 from $105, maintaining a Buy rating, following Monopar's initiation of a rolling NDA submission for ALXN1840 for Wilson disease. The stock has seen a significant 140% increase over the past year. The ALXN1840 drug has several FDA designations, including Fast Track, Orphan Drug, and Rare Pediatric Disease, with positive Phase 3 trial results demonstrating rapid and sustained copper mobilization.
